Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Japanese Anti-Coagulation Regimen Exploration in AF Catheter Ablation Registry - Rivaroxaban cohort

Next Previous
Trial Profile

Japanese Anti-Coagulation Regimen Exploration in AF Catheter Ablation Registry - Rivaroxaban cohort

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms JACRE-R
  • Sponsors Bayer Yakuhin

    • Most Recent Events

    • 28 Sep 2017 Results assessing the effects and risks of heparin bridging and different patterns of interruption/resumption of rivaroxaban on complications of catheter ablation for atrial fibrillation ,published in the Circulation Journal
    • 30 Aug 2017 Results a sub-analysis of JACRE Registry (n=1322; JACRE-R and JACRE-W )presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
    • 25 Oct 2016 Results assessing safety and efficacy from Rivaroxaban cohort (JACRE-R) and Warfarin cohort (JACRE-W) studies published in the Circulation Journal.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top